No Data
No Data
RBC Capital Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $74
Should You Hold Gilead Sciences (GILD)?
Gilead Sciences (GILD) Receives a Hold From RBC Capital
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
A Tech Reckoning Is Coming, Financial Pro Says. It's Time to Play Defense.